Welcome to our dedicated page for CervoMed news (Ticker: CRVO), a resource for investors and traders seeking the latest updates and insights on CervoMed stock.
CervoMed Inc. reports clinical-stage biotechnology developments centered on neflamapimod, an oral small-molecule drug candidate for age-related brain disorders. Company news most often covers dementia with Lewy bodies, the Phase 2b RewinD-LB trial, biomarker and MRI analyses, pharmacokinetic work, formulation and dosing disclosures, and regulatory interactions tied to later-stage development.
Updates also include financial results, grant revenue trends, investor conference presentations, shareholder voting matters, governance items, and capital-structure disclosures. CervoMed has also reported neflamapimod's inclusion in the UK EXPERTS-ALS platform for amyotrophic lateral sclerosis research.
CervoMed (NASDAQ: CRVO) reported Q1 2026 results and clinical progress for neflamapimod across several neurodegenerative indications.
Key points include finalized Phase 3 DLB trial design, new MRI and biomarker data, a new European patent to 2040, $12.9M cash and a $8.0M quarterly net loss.
CervoMed (NASDAQ: CRVO) reported MRI analyses from the RewinD-LB Phase 2b trial showing right basal forebrain (BF) volume increased with neflamapimod (+10.9 mm3, +3.5%) versus placebo decline (–13.3 mm3, –4.2%) at week 16 (p=0.022; p=0.028 percent change). Functional connectivity (right BF→DMN) rose 46% during the extension (p=0.014) and correlated with CDR-SB improvement (p=0.027, r2=0.43). Results were blinded, validated against autopsy pathology, and CervoMed plans a Phase 3 trial in DLB subject to financing.
CervoMed (NASDAQ: CRVO) provided a clinical update on neflamapimod at the 2026 Lewy Body Dementia Association Annual Meeting on April 7, 2026. The company reported finalized Phase 3 trial design and alignment with global regulators, plus new Phase 2b MRI analyses suggesting reduced basal forebrain atrophy and altered functional connectivity.
Additional MRI data will be presented at the 2026 American Academy of Neurology meeting on April 22, 2026. The company also highlighted plasma GFAP as a blood biomarker that correlated with clinical outcome (CDR‑SB) and showed responsiveness to treatment.
CervoMed (NASDAQ: CRVO) presented Phase 2b RewinD-LB analyses at AD/PD 2026 showing greater clinical benefit from neflamapimod in DLB patients with lower plasma pTau181 (indicative of absent AD co-pathology).
Within-participant comparisons show CDR-SB differences up to -1.11 (p=0.005) in the lowest pTau181 subgroup, a planned Phase 3 enrichment cutoff of <21 pg/mL, and a pharmacologic activity threshold of Ctrough 4 ng/mL.
CervoMed (NASDAQ: CRVO) reported positive Phase 2b RewinD-LB results and regulatory alignment for a planned Phase 3 in dementia with Lewy bodies (DLB).
The company selected 50 mg TID neflamapimod for the Phase 3 (~300 patients) and expects multiple catalysts in H2 2026. Cash was $20.9M at year-end 2025 with an estimated ~six-month runway; full-year 2025 net loss was $27.0M.
CervoMed (NASDAQ: CRVO) will present Phase 2b RewinD-LB analyses at AD/PD 2026 in Copenhagen, March 17-21, 2026. Presentations include an oral talk on March 21 and a symposium on March 20.
New secondary analyses by pre-specified plasma pTau181 and PK/PD data further support the planned Phase 3 dosing regimen and the chosen patient-enrichment cutoff for DLB patients without Alzheimer’s co-pathology.
CervoMed (NASDAQ: CRVO) announced management will participate in investor conferences in March 2026, including 1x1 investor meetings at the Leerink Global Healthcare Conference on March 11, 2026, and a fireside chat plus meetings at the 38th Annual ROTH Conference on March 23, 2026.
The ROTH fireside chat is scheduled for 12:00–12:30 PM PT on March 23, 2026; the webcast will be accessible in the Investor section of CervoMed's website.
CervoMed (NASDAQ: CRVO) completed a Phase 1 healthy volunteer study evaluating a new, stable crystal form of neflamapimod and selected 50 mg three times daily (TID) as the dosing regimen for its planned Phase 3 trial in dementia with Lewy bodies (DLB).
The company says the stable crystal form's pharmacokinetic profile largely overlaps with the clinically active DP Batch B from the Phase 2b extension; dose is increased to ensure target plasma concentrations are achieved.
CervoMed (NASDAQ: CRVO) announced on Feb 18, 2026 that neflamapimod was selected for inclusion in the UK EXPERTS-ALS platform to evaluate potential ALS treatments.
The randomized, multicenter, open-label trial will measure neurofilament light chain (NfL) in blood; initial evaluation targets ~35 patients for 18–24 weeks, with potential expansion to 80. Trial costs are funded by the UK NIHR and major motor neuron disease charities; first dosing expected by end of 2026.
CervoMed (NASDAQ: CRVO) reported late-breaking Phase 2b RewinD-LB results showing neflamapimod significantly slowed clinical progression in dementia with Lewy bodies (DLB) and reduced the biomarker plasma GFAP. In an extension phase using a new capsule batch (DP Batch B), CDR-SB worsening was 52% lower versus DP Batch A at week 16 (and 82% lower in patients with ptau181 <21 pg/mL). Effects were durable to 32 weeks and correlated with GFAP reductions (median -16.0; p<0.0001). Initial randomized phase did not meet the primary endpoint due to lower-than-expected bioavailability with DP Batch A. CervoMed plans a Phase 3 registrational trial in H2 2026.